{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T01:08:38Z","timestamp":1776992918109,"version":"3.51.4"},"reference-count":28,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T00:00:00Z","timestamp":1700352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ferring"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microorganisms"],"abstract":"<jats:p>The gut microbiota play a pivotal role in human health. Dysbiosis, alterations in microbiota composition and function, is associated with gastrointestinal disorders, including inflammatory bowel disease (IBD). This international survey aimed to assess physicians\u2019 experiences, perceptions, and practices related to microbiome modulation for gastrointestinal conditions, with a focus on IBD. Results from 142 healthcare professionals, predominantly gastroenterologists, confirmed a consensus on the relevance of the gut microbiota in IBD pathogenesis. However, the utilization of microbial composition analysis and probiotics in clinical practice was limited, primarily due to the lack of standardized guidelines and supporting evidence. Physicians held conflicting views on antibiotics, recognizing their potential for inducing remission but also causing flares in IBD. Respondents also had varying opinions on the efficacy of fecal microbiota transplantation (FMT) for different gastrointestinal conditions, with higher confidence in FMT effectiveness for irritable bowel syndrome with diarrhea, pouchitis, and ulcerative colitis. Concerns on FMT included uncertainty about effect duration, administration intervals, and conflicting evidence. Donor selection was believed to be a crucial factor in FMT outcomes. This survey highlights the need for further research and evidence-based guidelines to optimize the use of microbiome-based therapies in clinical practice. As our understanding of the gut microbiome continues to evolve, these insights will contribute to more informed and personalized approaches to managing gastrointestinal disorders.<\/jats:p>","DOI":"10.3390\/microorganisms11112806","type":"journal-article","created":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T00:30:50Z","timestamp":1700440250000},"page":"2806","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy, Safety, and Concerns on Microbiota Modulation, Antibiotics, Probiotics, and Fecal Microbial Transplant for Inflammatory Bowel Disease and Other Gastrointestinal Conditions: Results from an International Survey"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3398-0231","authenticated-orcid":false,"given":"Tommaso Lorenzo","family":"Parigi","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Digestive Endoscopy, IRCCS Ospedale San Raffaele, 20132 Milan, Italy"},{"name":"Division of Immunology, Transplantation and Infectious Disease, Universit\u00e0 Vita Salute San Raffele, 20132 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1859-7146","authenticated-orcid":false,"given":"Sophie","family":"Vieujean","sequence":"additional","affiliation":[{"name":"Hepato-Gastroenterology and Digestive Oncology, University Hospital CHU of Li\u00e8ge, 4000 Li\u00e8ge, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6865-5415","authenticated-orcid":false,"given":"Kristine","family":"Paridaens","sequence":"additional","affiliation":[{"name":"Ferring International Center S.A., CH-1162 Saint-Prex, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kira","family":"Dalgaard","sequence":"additional","affiliation":[{"name":"Ferring Pharmaceuticals A\/S, 2770 Kastrup, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nancy University Hospital, F-54500 Vand\u0153uvre-l\u00e8s-Nancy, France"},{"name":"INSERM, NGERE, University of Lorraine, F-54000 Nancy, France"},{"name":"INFINY Institute, Nancy University Hospital, F-54500 Vand\u0153uvre-l\u00e8s-Nancy, France"},{"name":"FHU-CURE, Nancy University Hospital, F-54500 Vand\u0153uvre-l\u00e8s-Nancy, France"},{"name":"Groupe Hospitalier Priv\u00e9 Ambroise Par\u00e9\u2013Hartmann, Paris IBD Center, F-92200 Neuilly sur Seine, France"},{"name":"Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, QC H4A3J1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Digestive Endoscopy, IRCCS Ospedale San Raffaele, 20132 Milan, Italy"},{"name":"Division of Immunology, Transplantation and Infectious Disease, Universit\u00e0 Vita Salute San Raffele, 20132 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nrgastro.2012.152","article-title":"The Gut Microbiota in IBD","volume":"9","author":"Manichanh","year":"2012","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/s41586-022-05435-0","article-title":"Effect of the Intratumoral Microbiota on Spatial and Cellular Heterogeneity in Cancer","volume":"611","author":"Wu","year":"2022","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1053\/j.gastro.2021.12.287","article-title":"Colorectal Cancer Screening in IBD\u2014Can Characterization of GI Microbiome Signatures Enhance Neoplasia Detection?","volume":"162","author":"Pratt","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41575-022-00581-2","article-title":"Microbiome Risk Profiles as Biomarkers for Inflammatory and Metabolic Disorders","volume":"19","author":"Metwaly","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S2468-1253(16)30108-X","article-title":"A Microbiota-Centric View of Diseases of the Upper Gastrointestinal Tract","volume":"2","author":"Nardone","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative Colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn\u2019s Disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide Incidence and Prevalence of Inflammatory Bowel Disease in the 21st Century: A Systematic Review of Population-Based Studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1053\/j.gastro.2023.05.032","article-title":"Gut Microbiome Composition Is Associated With Future Onset of Crohn\u2019s Disease in Healthy First-Degree Relatives","volume":"165","author":"Turpin","year":"2023","journal-title":"Gastroenterology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1136\/gutjnl-2017-314903","article-title":"Adherent-Invasive Escherichia Coli in Inflammatory Bowel Disease","volume":"67","author":"Palmela","year":"2018","journal-title":"Gut"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1136\/gutjnl-2022-328375","article-title":"Gut Virome-Colonising Orthohepadnavirus Genus Is Associated with Ulcerative Colitis Pathogenesis and Induces Intestinal Inflammation in Vivo","volume":"72","author":"Massimino","year":"2023","journal-title":"Gut"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1136\/gut.2003.037747","article-title":"Maintaining Remission of Ulcerative Colitis with the Probiotic Escherichia Coli Nissle 1917 Is as Effective as with Standard Mesalazine","volume":"53","author":"Kruis","year":"2004","journal-title":"Gut"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1053\/j.gastro.2020.12.040","article-title":"Ulcerative Colitis\u2014Maintanance of Remission With the Probiotic Escherichia Coli Strain Nissle 1917","volume":"160","author":"Stange","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1038\/ajg.2014.246","article-title":"Antibiotics Associated with Increased Risk of New-Onset Crohn\u2019s Disease but Not Ulcerative Colitis: A Meta-Analysis","volume":"109","author":"Ungaro","year":"2014","journal-title":"Am. J. Gastroenterol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1542-3565(05)00020-0","article-title":"Antibiotic Use and the Risk of Flare of Inflammatory Bowel Disease","volume":"3","author":"Aberra","year":"2005","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1053\/j.gastro.2020.09.038","article-title":"Fecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry","volume":"160","author":"Kelly","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Yau, Y.K., Shing Lau, L.H., Shun Lui, R.N., Wong, S.H., Guo, C.L., Yan Mak, J.W., Ling Ching, J.Y., Ip, M., Kamm, M.A., and Rubin, D.T. (2023). Long-Term Safety Outcomes of Fecal Microbiota Transplantation: Real-World Data Over 8 Years From the Hong Kong FMT Registry. Clin. Gastroenterol. Hepatol., online ahead of print.","DOI":"10.1016\/j.cgh.2023.09.001"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Wilson, B.C., Vatanen, T., Cutfield, W.S., and O\u2019Sullivan, J.M. (2019). The Super-Donor Phenomenon in Fecal Microbiota Transplantation. Front. Cell. Infect. Microbiol., 9.","DOI":"10.3389\/fcimb.2019.00002"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1136\/gutjnl-2019-319548","article-title":"International Consensus Conference on Stool Banking for Faecal Microbiota Transplantation in Clinical Practice","volume":"68","author":"Cammarota","year":"2019","journal-title":"Gut"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/gutjnl-2016-313017","article-title":"European Consensus Conference on Faecal Microbiota Transplantation in Clinical Practice","volume":"66","author":"Cammarota","year":"2017","journal-title":"Gut"},{"key":"ref_21","unstructured":"US Food and Drug Administration (2023, October 06). FDA Approves First Fecal Microbiota Product, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-fecal-microbiota-product."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2468-1253(22)00085-1","article-title":"Difficult-to-Treat Inflammatory Bowel Disease: Results from a Global IOIBD Survey","volume":"7","author":"Parigi","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_23","unstructured":"Tun, H.M., Peng, Y., Massimino, L., Sin, Z.Y., Parigi, T.L., Facoetti, A., Rahman, S., Danese, S., and Ungaro, F. (2023). Gut Virome in IBD and Beyond. Gut, online ahead of print."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1093\/ibd\/izab343","article-title":"The Neglected Gut Microbiome: Fungi, Protozoa, and Bacteriophages in Inflammatory Bowel Disease","volume":"28","author":"Guzzo","year":"2022","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/s41586-022-04502-w","article-title":"Immune Regulation by Fungal Strain Diversity in Inflammatory Bowel Disease","volume":"603","author":"Li","year":"2022","journal-title":"Nature"},{"key":"ref_26","first-page":"CD013871","article-title":"Fecal Microbiota Transplantation for the Treatment of Recurrent Clostridioides Difficile (Clostridium Difficile)","volume":"4","author":"Minkoff","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1053\/j.gastro.2018.12.019","article-title":"Fecal Microbiota Transplantation Is Superior to Fidaxomicin for Treatment of Recurrent Clostridium Difficile Infection","volume":"156","author":"Hvas","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1056\/NEJMc1803103","article-title":"Fecal Microbiota Transplantation for Primary Clostridium Difficile Infection","volume":"378","author":"Juul","year":"2018","journal-title":"N. Engl. J. Med."}],"container-title":["Microorganisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2607\/11\/11\/2806\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:25:39Z","timestamp":1760131539000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2607\/11\/11\/2806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,19]]},"references-count":28,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["microorganisms11112806"],"URL":"https:\/\/doi.org\/10.3390\/microorganisms11112806","relation":{},"ISSN":["2076-2607"],"issn-type":[{"value":"2076-2607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,19]]}}}